Jaguar Health, Inc. (JAGX)
| Market Cap | 3.59M |
| Revenue (ttm) | 11.55M |
| Net Income (ttm) | -39.73M |
| Shares Out | 1.32M |
| EPS (ttm) | -93.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 135,065 |
| Open | 2.860 |
| Previous Close | 2.920 |
| Day's Range | 2.640 - 2.890 |
| 52-Week Range | 2.611 - 110.750 |
| Beta | 0.70 |
| Analysts | Strong Buy |
| Price Target | 60.00 (+2,114.02%) |
| Earnings Date | Aug 12, 2025 |
About JAGX
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiret... [Read more]
Financial Performance
In 2024, Jaguar Health's revenue was $11.69 million, an increase of 19.75% compared to the previous year's $9.76 million. Losses were -$38.49 million, -6.80% less than in 2023.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for JAGX stock is "Strong Buy" and the 12-month stock price forecast is $60.0.
News
Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset
Strategic decision positions Jaguar to diversify treasury holdings with a long-term digital store of value SAN FRANCISCO, CA / ACCESS Newswire / June 26, 2025 / Jaguar Health, Inc. ( NASDAQ:JAGX) ("J...
Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs
Canalevia® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for treatment of chemotherapy-induced diarrhea in dogs Jaguar is exploring the possi...
Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026
Company's CEO, board members, other C-suite members, and institutional and accredited investors are participants in the extension of the bridge financing SAN FRANCISCO, CA / ACCESS Newswire / June 24,...
Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer
Enrollment in company's first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for microvillus inclusion disease (MVID) in pediatric patients has reached approximate...
Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts
Click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 17, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present v...
First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
Two parallel goals for Canalevia-CA1 (crofelemer delayed-release tablets): To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) and to expand the indication of crof...
REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners' Spring 2025 Spotlight Series
Click here to register Discussion will focus on company's May 2025 meeting with the FDA to review the statistically significant responder analysis results for the subgroup of breast cancer patients in...
Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer
Productive and collaborative discussion on proposed pathway by the company to bring crofelemer to approval for cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving...
Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners' Spring 2025 Spotlight Series
Click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 6, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will participat...
Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SAN FRANCISCO, CA / ACCESS Newswire / May 21, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), today announced that it has entered into definitive agreements for the purchase and ...
First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID)
As announced , initial proof-of-concept (POC) results from distinct ongoing investigator-initiated trial (IIT) in Abu Dhabi show crofelemer reduced total parenteral support in a pediatric MVID patient...
Jaguar Health, Inc. (JAGX) Q1 2025 Earnings Call Transcript
Jaguar Health, Inc. (NASDAQ:JAGX) Q1 2025 Earnings Conference Call May 15, 2025 4:15 PM ET Company Participants Lisa Conte – Founder, President, and Chief Executive Officer Carol Lizak – Chief Financ...
Jaguar Health Reports First Quarter 2025 Financials
The combined net Q1 2025 revenue of approximately $2.2 million for prescription and non-prescription products, including license revenue, decreased approximately 6% versus net Q1 2024 revenue of $2.4 ...
Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates
Click here to register Company plans to file its Earnings Report on May 15, 2025 on Form 10-Q for the quarter ended March 31, 2025 SAN FRANCISCO, CA / ACCESS Newswire / May 14, 2025 / Jaguar Health, I...
Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs
Company's Canalevia®-CA1 (crofelemer delayed-release tablets) prescription drug is FDA conditionally approved for treatment of chemotherapy-induced diarrhea (CID) in dogs and is the first and only tre...
Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts
Crofelemer is the only oral drug approved by the FDA's Center for Drug Evaluation and Research under Botanical Guidance Click here to access replay of company's April 30, 2025 investor webcast SAN FRA...
Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease Progression in Intestinal Failure Patients
Jaguar to host investor webcast today at 8:30 AM Eastern to review the initial results from the proof-of-concept study of crofelemer for MVID and SBS-IF presented April 26 at the Annual ELITE PED-GI C...
REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF)
The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for c...
Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast
The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for c...
Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress
Crofelemer, a novel plant-based anti-secretory prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome (SBS) and mi...
Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting
The statistically significant responder analysis results for Mytesi® (crofelemer) in the Phase 3 OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 20...
Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product
Gelclair ® is the company's third commercialized prescription product Oral mucositis, also called "chemo mouth," a painful inflammation of the mouth's mucous membranes, has emerged as the most signifi...
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 4, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective April 3, 2025, the Company granted 3,600 res...
Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules
SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 1, 2025 / Jaguar Health, Inc. ( NASDAQ:JAGX) ("Jaguar" or "the Company"), today announced the closing of its previously announced private placement...
Jaguar Health, Inc. (JAGX) Q4 2024 Earnings Call Transcript
Jaguar Health, Inc. (NASDAQ:JAGX) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Conference Call Participants Operator Greetings, and welcome to the Jaguar Health Inv...